8-K: Delcath Systems Reports Strong Q3 2025 Revenue Growth

Delcath Systems announced robust third-quarter 2025 financial results, driven by significant HEPZATO KIT revenue growth and positive clinical trial advancements.

Summary

• Total revenue for Q3 2025 was $20.6 million, an 83.9% increase from $11.2 million in Q3 2024.
• HEPZATO KIT revenue grew 93% to $19.3 million in Q3 2025 from $10.0 million in Q3 2024.
• Gross margins improved to 87% in Q3 2025, up from 85% in Q3 2024.
• Non-GAAP adjusted EBITDA was positive $5.3 million in Q3 2025, a significant increase from $1.0 million in Q3 2024.
• Cash provided by operations was $4.8 million in Q3 2025, a substantial improvement from $3.6 million used by operations in Q3 2024.
• Net income decreased to $0.8 million in Q3 2025 from $1.9 million in Q3 2024, primarily due to increased R&D and SG&A expenses for growth initiatives.
• The company initiated a global Phase 2 trial for HEPZATO in liver-dominant metastatic colorectal cancer, with topline data expected in 2028.
• Positive results from the CHOPIN trial for CHEMOSAT in metastatic uveal melanoma were presented, showing improved one-year progression-free survival.
• Full-year 2025 revenue guidance is set between $83 million and $85 million, representing approximately 150% volume increase over 2024.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue growth, improved gross margins, and a significant positive shift in adjusted EBITDA and cash from operations. Positive clinical trial advancements and robust full-year guidance contribute to a very positive outlook, despite a temporary dip in GAAP net income due to growth-related expenses.

Positives

• Total revenue increased by 83.9% to $20.6 million in Q3 2025 compared to $11.2 million in Q3 2024.
• HEPZATO KIT revenue surged by 93% to $19.3 million in Q3 2025 from $10.0 million in Q3 2024.
• Gross margins improved to 87% in Q3 2025, up from 85% in Q3 2024.
• Non-GAAP adjusted EBITDA was positive $5.3 million in Q3 2025, a significant increase from $1.0 million in Q3 2024.
• Cash provided by operations was $4.8 million in Q3 2025, a substantial improvement from $3.6 million used by operations in Q3 2024.
• Cash and investments stood at $88.9 million as of September 30, 2025, with no debt.
• First patient dosed in a global Phase 2 trial for HEPZATO in liver-dominant metastatic colorectal cancer.
• Positive results from the investigator-initiated Phase 2 CHOPIN trial for CHEMOSAT in metastatic uveal melanoma, showing significant improvement in one-year progression-free survival.
• Full-year 2025 revenue guidance of $83 million to $85 million implies a 150% volume increase over 2024.
• Guidance for positive adjusted EBITDA and cashflow in each quarter of 2025.

Negatives

• Net income decreased to $0.8 million in Q3 2025 from $1.9 million in Q3 2024.
• Revenue results in the quarter reflected the impact of NDRA discounts and seasonal factors.
• Research and development expenses increased by 105% to $8.0 million, driven by clinical team expansion and new Phase 2 trials.
• Selling, general and administrative expenses increased by 47.1% to $10.3 million due to commercial expansion activities and additional personnel.

Risks

• Uncertainties relating to the company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT.
• Risks associated with contributions to adjusted EBITDA.
• Challenges in successfully managing the HEPZATO KIT supply chain, including securing adequate supply of critical components.
• Dependence on successful FDA inspections of the company's facilities and those of its third-party suppliers/manufacturers.
• The company's ability to successfully implement and manage the HEPZATO KIT Risk Evaluation and Mitigation Strategy.
• Uncertainties regarding the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver.
• Risks related to the company's ability to obtain reimbursement for the HEPZATO KIT.
• Challenges in successfully entering into any necessary purchase and sale agreements with users of the HEPZATO KIT.

Future Outlook

Delcath Systems projects total CHEMOSAT and HEPZATO KIT revenue for the full fiscal year 2025 to be in the range of $83 million to $85 million, representing an approximate 150% increase in volume over 2024. The company also anticipates gross margins to be between 85% and 87% and expects to achieve positive adjusted EBITDA and cashflow in each quarter of 2025.

Management Comments

• We made strong progress with our clinical programs, reporting compelling positive CHOPIN results and first-patient dosing in our global Phase 2 trial in liver-dominant metastatic colorectal cancer.
• While revenue results in the quarter reflected the impact of NDRA discounts and seasonal factors, our fundamentals remain strong.
• We are confident that the growing clinical validation of HEPZATO positions us well to drive continued progress and long-term value for patients and shareholders.

Industry Context

Delcath Systems operates in the interventional oncology space, a growing segment focused on targeted treatments for liver cancers. The positive clinical trial results for HEPZATO and CHEMOSAT, particularly in metastatic uveal melanoma and the initiation of a trial for metastatic colorectal cancer, demonstrate the company's commitment to expanding its therapeutic applications. These advancements align with broader industry trends towards precision medicine and combination therapies to improve patient outcomes in challenging cancer types.

Comparison to Industry Standards

• The reported 87% gross margin is generally considered very strong within the biotechnology and pharmaceutical sectors, often indicating efficient production or high-value proprietary products.
• The significant year-over-year total revenue growth of 83.9% and HEPZATO KIT revenue growth of 93% suggests rapid market penetration and adoption, which is highly competitive in the oncology drug market.
• The shift from cash used by operations to cash provided by operations ($4.8 million provided in Q3 2025 vs. $3.6 million used in Q3 2024) is a positive indicator of increasing operational efficiency and market acceptance, often seen in successful commercialization phases of biotech companies.

Stakeholder Impact

• Shareholders: Positive financial results, strong guidance, and clinical progress are likely to enhance shareholder value.
• Patients: Advancements in clinical trials for HEPZATO and CHEMOSAT offer potential new treatment options for liver cancers, including metastatic uveal melanoma and metastatic colorectal cancer.
• Employees: Expansion of clinical and commercial teams suggests job growth and stability.
• Customers (Medical Centers): Expansion to 25 active centers across the U.S. indicates increased access to HEPZATO KIT.

Next Steps

• Continue commercialization of HEPZATO KIT in the U.S.
• Enroll approximately 90 patients across 20+ sites in the U.S. and Europe for the global Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer.
• Anticipate topline data from the global Phase 2 trial in 2028.
• Host a conference call on November 6, 2025, to discuss Q3 2025 results.

Key Dates

Recommendation

The company has demonstrated exceptional year-over-year revenue growth, particularly with its flagship HEPZATO KIT, alongside significant improvements in gross margins and a strong positive shift in adjusted EBITDA and cash flow from operations. The robust full-year 2025 guidance, projecting a 150% volume increase, indicates continued strong momentum. Furthermore, positive clinical trial results and the initiation of new Phase 2 trials expand the potential market and clinical validation for their products. While net income saw a temporary dip, it is attributable to strategic investments in R&D and commercial expansion, which are crucial for long-term growth. The strong balance sheet with $88.9 million in cash and no debt provides a solid foundation for future operations and growth initiatives. These factors collectively suggest a strong growth trajectory and undervaluation potential, warranting a 'strong buy' recommendation for seasoned investors.

Keywords

Delcath Systems, DCTH, Interventional Oncology, Liver Cancer, HEPZATO KIT, CHEMOSAT, Metastatic Uveal Melanoma, Metastatic Colorectal Cancer, Q3 2025 Earnings, Financial Results, Clinical Trials, Biotechnology, Pharmaceuticals